Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Talzenna talazoparib Metastatic castration-resistant prostate cancer (mCRPC) Suspended
Tarceva Erlotinib Cancer, Lung , non-small cell List with clinical criteria and/or conditions Complete
Targin Oxycodone / naloxone Pain, Moderate to severe and relief of opioid-induced constipation Cancelled
Targin Oxycodone HCI / naloxone HCI Pain, moderate to severe and relief of opioid-induced constipation Do not list Complete
Tavalisse fostamatinib Chronic immune thrombocytopenia Do not reimburse Complete
Tavneos avacopan Antineutrophil cytoplasmic antibody-associated vasculitis Do not reimburse Complete
TBC risperidone Schizophrenia, adults Suspended
TBC abaloparatide Osteoporosis, postmenopausal women Withdrawn
TBC tirzepatide Diabetes mellitus, type 2 Cancelled
TBC filgrastim Prevention or treatment of neutropenia in various indications Cancelled